DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more



Pharmacokinetic Study With Colchicine in Healthy Volunteers

Information source: Mutual Pharmaceutical Company, Inc.
ClinicalTrials.gov processed this data on August 20, 2015
Link to the current ClinicalTrials.gov record.

Condition(s) targeted: Pharmacokinetics

Intervention: colchicine tablets (Drug); colchicine tablets (Drug)

Phase: Phase 1

Status: Completed

Sponsored by: Mutual Pharmaceutical Company, Inc.

Official(s) and/or principal investigator(s):
Anthony R Godfrey, Pharm.D., Principal Investigator, Affiliation: PRACS Institiute, Ltd.

Summary

This open label, single group, sequential dose study will compare the single dose pharmacokinetics of colchicine 0. 6 mg given orally to colchicine pharmacokinetics after 10 days of a standard prophylactic dose (0. 6 mg every 12 hours) in healthy volunteers.

Clinical Details

Official title: An Open Label, Two Period, Sequential, Single Dose and Multiple Dose Pharmacokinetic Study With 0.6mg Colchicine Tablets in Healthy Volunteers

Study design: Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science

Primary outcome:

Maximum Serum Concentration (Cmax)

Area Under the Concentration Versus Time Curve From Time Zero to the Time of the Last Measured Level.

Area Under the Concentration Versus Time Curve From Zero to Infinity (AUC 0-inf)

Detailed description: This open label, single group, sequential dose study will compare the single dose pharmacokinetics of colchicine 0. 6 mg given orally to colchicine pharmacokinetics after 10 days of a standard prophylactic dose (0. 6 mg every 12 hours) in healthy volunteers. After a fast of at least 10 hours, fourteen healthy non-smoking, non-obese, non-pregnant volunteers will receive a single oral dose of colchicine 0. 6 mg. Fasting will continue for 4 hours after the dose, at which time a standard meal will be served. Blood will be drawn from all participants at times sufficient to adequately define the single dose pharmacokinetics of colchicine and its 3 major metabolites, 2, 3 and 10 demethylcolchicine. Following a 14 day washout period, all participants will begin a 10 day regimen of colchicine 0. 6 mg orally every 12 hours. On the morning of day 25, after a fast of at least 10 hours, all participants will receive their final dose of colchicine 0. 6 mg. Again blood will be drawn at times sufficient to determine the pharmacokinetics of colchicine and its 3 major metabolites after chronic dosing. The pharmacokinetic parameters for each dosing situation will be derived and compared for relevant differences. Though not a specific goal of this study, all participants will be monitored for adverse events by observation and query during periods of confinement on days 1, 15 and 25, as well as by complete blood count (CBC) with differential and clinical chemistry, sitting and standing blood pressures, and heart rate and 12-lead electrocardiogram (EKG) before and after dosing, on days 1 and 25.

Eligibility

Minimum age: 18 Years. Maximum age: 45 Years. Gender(s): Both.

Criteria:

Inclusion Criteria:

- Completion of the screening process within 28 days prior to Period I dosing

- Healthy non-smoking, non-obese adult men and women volunteers between the ages of 18

to 45 years of age, weighing at least 110 with a body mass index of 18-30kg/m2

- Women must be postmenopausal, surgically sterile, commit to abstinence from

heterosexual sexual contact or use two methods of contraception. Exclusion Criteria:

- Pregnant or lactating

- Use of any investigational drug within 28 days prior to Period I dosing.

- Presence or history of a clinically significant disorder involving the

cardiovascular, respiratory, renal, gastrointestinal, immunologic, hematologic, endocrine, or neurologic system(s) or psychiatric disease as determined by the clinical investigator(s)

- Positive screen for human immunodeficiency virus (HIV), hepatitis B surface antigen

(HbsAg), or hepatitis C virus (HCV)

- Clinical laboratory test values outside the accepted reference range and when

confirmed on re-examination.

- Any clinically significant illness during the 4 weeks prior to Period I dosing (as

determined by the clinical investigators)

- Use of any systemic prescription medication in the 14 days prior to Period I dosing

- History of any allergy(s) including allergy to colchicine or related drugs.

- History of drug or alcohol addiction or abuse within the past year or a positive drug

abuse screen

- Currently or recent (within 6 months) use of tobacco products prior to dose

administration

- Donation of greater than 150 mL of blood within 28 days or plasma within 14 days

prior to period I dosing

Locations and Contacts

PRACS Institute, Ltd. - Cetero Research, Fargo, North Dakota 58104, United States
Additional Information

Recalls, Market Withdrawals and Safety Alerts

Daily Med - Posting of Recently Submitted Labeling to the FDA

Starting date: September 2007
Last updated: October 5, 2009

Page last updated: August 20, 2015

-- advertisement -- The American Red Cross
 
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2017